Risk of venous thromboembolism according to molecular profiling in patients with neuroendocrine carcinoma

#4200

Introduction: Venous thromboembolism (VTE) is a common complication in cancer patients, which negatively affects prognosis. Neuroendocrine carcinomas (NEC) are a rare and aggressive diseases, with low responses to treatment and poor prognosis. In this context, the use of molecular profiling is crucial for the identification of druggable alterations. However, data about VTE in NENs are scares, even though retrospective data describes rates in line with other high-risk malignancies.

Aim(s): Our aim is to describe the rate of VTE and its potential association with specific molecular alterations in NEC.

Materials and methods: We conducted a retrospective study enrolling patients with metastatic NEC evaluated at IEO from 2021 to 2023. Clinical information were collected from medical records, including VTE events as pulmonary embolism (PE), deep vein thrombosis (DVT) and visceral venous thrombosis (VVT). A custom Next-Generation Sequencing (NGS) panel will be performed on tumor specimens, assessing mutational status of 26 tumor-genes and microsatellite instability.

Conference:

Presenting Author:

Authors: Gervaso L, Winchler C, Pisa E, Benini L, Cella C,

Keywords: VTE, NEC, molecular profiling, neuroendocrine carcinoma, venous thromboembolism,